ABEO trades 194.6% below Wall Street's consensus target of $17.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes ABEO achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 9 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of June 23, 2026, Abeona Therapeutics Inc. (ABEO) has a Wall Street consensus price target of $17.00, based on estimates from 9 covering analysts. With the stock currently trading at $5.75, this represents a potential upside of +194.6%. The company has a market capitalization of $328M.
Analyst price targets range from a low of $17.00 to a high of $17.00, representing a 0% spread in expectations. The median target of $17.00 aligns closely with the consensus average. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,3 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, ABEO trades at a trailing P/E of 5.7x. Analysts expect EPS to grow -161.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $0.10, with bear and bull scenarios of $0.06 and $0.13 respectively. Model confidence stands at 51/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
KRYSKrystal Biotech, Inc. | $10.1B | $343.43 | $336.40 | -3.4% | Buy | 44.9x | 17 |
RAREUltragenyx Pharmaceutical Inc. | $2.9B | $29.03 | $48.36 | +76.2% | Buy | — | 33 |
FOLDAmicus Therapeutics, Inc. | $4.5B | $14.49 | $14.50 | +0.1% | Buy | 40.6x | 24 |
ACADACADIA Pharmaceuticals Inc. | $3.8B | $22.09 | $33.67 | +55.7% | Buy | 55.6x | 37 |
RCKTRocket Pharmaceuticals, Inc. | $378M | $3.46 | $5.00 | +49.3% | Buy | — | 19 |
BEAMBeam Therapeutics Inc. | $3.7B | $35.53 | $48.00 | +40.6% | Buy | — | 27 |
SGMOSangamo Therapeutics, Inc. | $73M | $0.17 | $7.25 | +3927.8% | Hold | — | 14 |
CRSPCRISPR Therapeutics AG | $5.2B | $54.36 | $71.67 | +32.5% | Buy | — | 38 |
EDITEditas Medicine, Inc. | $274M | $2.80 | $5.00 | +85.9% | Buy | — | 25 |
NTLAIntellia Therapeutics, Inc. | $1.8B | $15.75 | $26.13 | +66.8% | Buy | — | 39 |
Quick answers to the most common questions about buying ABEO stock.
The consensus Wall Street price target for ABEO is $17, representing 194.6% upside from the current price of $5.75. With 9 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
ABEO has a consensus rating of "Buy" based on 9 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $17 implies 194.6% upside from current levels.
ABEO's current price is $5.75 with a consensus target of $17 (194.6% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $17 for ABEO, while the most conservative target is $17. The consensus of $17 represents the median expectation. Our quantitative valuation model projects a bull case target of $0 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
ABEO is moderately covered, with 9 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 3 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month ABEO stock forecast based on 9 Wall Street analysts shows a consensus price target of $17, with estimates ranging from $17 (bear case) to $17 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $0, with bear/bull scenarios of $0/$0.
Our quantitative valuation model calculates ABEO's fair value at $0 (base case), with a bear case of $0 and bull case of $0. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.
Wall Street analysts are very optimistic on ABEO, with a "Buy" consensus rating and $17 price target (194.6% upside). 6 of 9 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
ABEO analyst price targets range from $17 to $17, a 0% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $17 consensus represents the middle ground. Our model's $0-$0 range provides an independent fundamental perspective.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.